A phase II, open label, randomized comparative multi-center study to compare the efficacy and tolerability of olaparib in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with platinum sensitive advanced serous ovarian cancer.
Purpose:
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin when compared with carboplatin and paclitaxel alone in patients with advanced ovarian cancer.
Primary endpoint:
Progression free survival
Secondary endpoints:
Percentage change in tumor size, to compare the safety and tolerability by collection of adverse events, hematology, clinical chemistry data, vital signs
Participating countries:
Australia, Belgium, Canada, Czech Republic, Germany, Italy, Japan, Netherlands, Panama, Peru, Spain, United Kingdom, United States
Olaparib is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.
For more information, please contact: Cancer Study Locator service, sponsored by AstraZeneca at 1-877-400-4656 or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov
Download PDF (PDF— 1610 KB)
Next: Enthuse M0 Clinical Trial for Prostate Cancer